Windtree announces FDA Fast Track Designation for istaroxime
Windtree Therapeutics announced the FDA has granted Fast Track Designation for istaroxime for the treatment of acute heart failure. Istaroxime is a first-in-class, dual action, luso-inotropic agent in clinical development for treatment of acute heart failure with reduced ejection fraction. August 13, 2019
